Analysis of Α-Synuclein Species Enriched from Cerebral Cortex of Humans with Sporadic Dementia with Lewy Bodies.

John B. Sanderson,Suman De,Haiyang Jiang,Matteo Rovere,Ming Jin,Ludovica Zaccagnini,Aurelia Hays Watson,Laura De Boni,Valentina N. Lagomarsino,Tracy L. Young-Pearse,Xinyue Liu,Thomas C. Pochapsky,Bradley T. Hyman,Dennis W. Dickson,David Klenerman,Dennis J. Selkoe,Tim Bartels
DOI: https://doi.org/10.1093/braincomms/fcaa010
2020-01-01
Brain Communications
Abstract:Since researchers identified α-synuclein as the principal component of Lewy bodies and Lewy neurites, studies have suggested that it plays a causative role in the pathogenesis of dementia with Lewy bodies and other 'synucleinopathies'. While α-synuclein dyshomeostasis likely contributes to the neurodegeneration associated with the synucleinopathies, few direct biochemical analyses of α-synuclein from diseased human brain tissue currently exist. In this study, we analysed sequential protein extracts from a substantial number of patients with neuropathological diagnoses of dementia with Lewy bodies and corresponding controls, detecting a shift of cytosolic and membrane-bound physiological α-synuclein to highly aggregated forms. We then fractionated aqueous extracts (cytosol) from cerebral cortex using non-denaturing methods to search for soluble, disease-associated high molecular weight species potentially associated with toxicity. We applied these fractions and corresponding insoluble fractions containing Lewy-type aggregates to several reporter assays to determine their bioactivity and cytotoxicity. Ultimately, high molecular weight cytosolic fractions enhances phospholipid membrane permeability, while insoluble, Lewy-associated fractions induced morphological changes in the neurites of human stem cell-derived neurons. While the concentrations of soluble, high molecular weight α-synuclein were only slightly elevated in brains of dementia with Lewy bodies patients compared to healthy, age-matched controls, these observations suggest that a small subset of soluble α-synuclein aggregates in the brain may drive early pathogenic effects, while Lewy body-associated α-synuclein can drive neurotoxicity.
What problem does this paper attempt to address?